Efects of melatonin and octreotide on peridural fibrosis in an animal model of laminectomy.
OBJECTIVE
To investigate the effects of melatonin and octreotide in the prevention of peridural fibrosis in an experimental rat model.


METHODS
A total of 36 rats were divided into three groups: Group I was laminectomized and not given any treatment. Group II received an intraperitoneal 30 microg/kg/day dose of octreotide for six weeks after the laminectomy. Group III rats were injected with melatonin 7.5 mg/kg/day for six weeks after the laminectomy. At the end of six weeks, plasma transforming growth factor beta-1 levels and peridural fibrous tissue hydroxyproline concentrations were determined and histopathological examinations was performed.


RESULTS
Serum TGF-Beta1 levels of the octreotide and melatonin groups were found to be lower than the control group. The lower levels of TGF-Beta1 was statistically significant in both of the groups. Hydroxyproline levels of the octreotide and melatonin groups were found to be lower than that of the control group. The decrease was statistically significant only in the melatonin group. Peridural fibrosis scores of the octreotide and melatonin groups were lower than the control group. This histopathological improvement was statistically significant only in the melatonin group.


CONCLUSIONS
Melatonin and octreotide prevented TGF-Beta1 increase in peridural fibrosis, but only melatonin significantly improved hyroxyproline levels and fibrosis scores as demonstrated.
Erol
Fatih Serhat
FS
Firat University, Faculty of Medicine, Department of Neurosurgery, Elaziğ, Turkey. fserol@yahoo.com
Kavakli
Ahmet
A
Ilhan
Necip
N
Ozercan
Ibrahim Hanifi
IH
Sarsilmaz
Mustafa
M
D000818:Animals; D002492:Central Nervous System Depressants / Q000494:pharmacology / Q000627:therapeutic use; D005355:Fibrosis / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D007796:Laminectomy / Q000379:methods*; D008159:Lumbar Vertebrae; D008297:Male; D008550:Melatonin / Q000494:pharmacology / Q000627:therapeutic use*; D015282:Octreotide / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D053773:Transforming Growth Factor beta1 / Q000097:blood
D002492:Central Nervous System Depressants; D053773:Transforming Growth Factor beta1; D008550:Melatonin; D015282:Octreotide